Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.

JCI insight - 25 Jan 2021

Lee Sang Eun, Lee Seung-Ju, Kim Song-Ee, Kim Kinam, Cho Boyoung, Roh Kyounghwan, Kim Soo-Chan

Abstract excerpt

BACKGROUNDRecessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease that causes severe mucocutaneous fragility due to mutations in COL7A1 (encoding type VII collagen [C7]). In this phase I/IIa trial, we evaluated the safety and possible clinical efficacy of intravenous infusion of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in patients with RDEB.METHODSFour...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allografts
Share to Collagen Type VII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cord Blood Stem Cell Transplantation

Share to Epidermolysis Bullosa Dystrophica

Share to Infusions, Intravenous

Share to Mesenchymal Stem Cell Transplantation

Share to Pain Measurement

Share to Pruritus

Source

Open in PubMed Open full text

Identifiers

PMID: 33491668
DOI: 10.1172/jci.insight.143606
PMCID: PMC7934866

Genes

C7
MSC
COL7A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.PMID 33491668Read ↗

Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosaSemantic proximity Read ↗

Treatment of Epidermolysis Bullosa and Future Directions: A ReviewSemantic proximity Read ↗

Rescue of the Mucocutaneous Manifestations by Human Cord Blood Derived Nonhematopoietic Stem Cells in a Mouse Model of Recessive Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

Promising effect of intravenous immunoglobulin therapy for epidermolysis bullosa pruriginosa.Semantic proximity Read ↗

Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trialSemantic proximity Read ↗

Generation of the induced pluripotent stem cell line (ZSPHARi001-A) from a patient with recessive dystrophic epidermolysis bullosa carrying compound heterozygous mutation in the COL7A1 gene.Semantic proximity Read ↗

Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin GraftsSemantic proximity Read ↗

EB2017-Progress in Epidermolysis Bullosa Research toward Treatment and Cure.Semantic proximity Read ↗

Characterization of patients with dystrophic epidermolysis bullosa for collagen VII therapySemantic proximity Read ↗

Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.